Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.
Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.
复制标题
Epstein-Barr 病毒糖蛋白 gH/gL 抗体与 IgA 病毒衣壳抗原互补以诊断鼻咽癌
DOI：
10.18632/oncotarget.7688
复制
发表时间：
2016-03-29
期刊：
影响因子：
--
通讯作者：
Huang XM
中科院分区：
文献类型：
--
作者：
Li RC;Du Y;Zeng QY;Tang LQ;Zhang H;Li Y;Liu WL;Zhong Q;Zeng MS;Huang XM
为探讨血清中抗EB病毒（EBV）糖蛋白gH/gL抗体的检测是否能提高鼻咽癌（NPC）诊断的准确性，采用重组杆状病毒表达系统表达的gH/gL抗体进行酶联免疫吸附试验（ELISA），检测两个独立队列的抗体。使用来自训练队列（n = 406）的结果进行二元逻辑回归分析以建立诊断数学模型，其在第二个独立队列（n = 279）中进行验证。鼻咽癌患者血清gH/gL抗体水平明显高于健康对照组（P < 0.001）。在训练队列中，IgA-gH/gL ELISA诊断NPC的敏感性为83.7%，特异性为82.3%，曲线下面积（AUC）为0.893（95%CI，0.862-0.924）。此外，gH/gL在IgA-VCA阴性的NPC患者中保持了诊断能力（灵敏度= 78.1%，特异性= 82.3%，AUC = 0.879 [95%CI，0.820 - 0.937]）。在两个培训队列中，与单独的单独检测相比，gH/gL和病毒衣壳抗原（VCA）检测的组合提高了诊断能力。（灵敏度= 88.5%，特异性= 97%，AUC = 0.98 [95%CI，0.97 - 0.991]），验证队列（灵敏度= 91.2%，特异性= 96.5%，AUC = 0.97 [95%CI，0.951-0.988]）。这些结果表明，EBV gH/gL检测补充VCA检测在鼻咽癌的诊断和艾滋病与VCA阴性的鼻咽癌患者的识别。
To determine whether measuring antibodies against Epstein-Barr virus (EBV) glycoprotein gH/gL in serum could improve diagnostic accuracy in nasopharyngeal carcinoma (NPC) cases, gH/gL expressed in a recombinant baculovirus system was used in an enzyme-linked immunosorbent assay (ELISA) to detect antibodies in two independent cohorts. Binary logistic regression analyses were performed using results from a training cohort (n = 406) to establish diagnostic mathematical models, which were validated in a second independent cohort (n = 279). Levels of serum gH/gL antibodies were higher in NPC patients than in healthy controls (p < 0.001). In the training cohort, the IgA-gH/gL ELISA had a sensitivity of 83.7%, specificity of 82.3% and area under the curve (AUC) of 0.893 (95% CI, 0.862-0.924) for NPC diagnosis. Furthermore, gH/gL maintained diagnostic capacity in IgA-VCA negative NPC patients (sensitivity = 78.1%, specificity = 82.3%, AUC = 0.879 [95% CI, 0.820 - 0.937]). Combining gH/gL and viral capsid antigen (VCA) detection improved diagnostic capacity as compared to individual tests alone in both the training cohort (sensitivity = 88.5%, specificity = 97%, AUC = 0.98 [95% CI, 0.97 - 0.991]), and validation cohort (sensitivity = 91.2%, specificity = 96.5%, AUC = 0.97 [95% CI, 0.951-0.988]). These findings suggest that EBV gH/gL detection complements VCA detection in the diagnosis of NPC and aids in the identification of patients with VCA-negative NPC.